title: Anti-D administration after spontaneous miscarriage for preventing Rhesus alloimmunisation.
abstract: BACKGROUND
  During pregnancy, a Rhesus-negative (Rh-negative) woman may develop antibodies if her fetus is Rh-positive, which can cause fetal morbidity or mortality in following pregnancies, if untreated.
  
  
  OBJECTIVE
  To assess the effects of administering anti-D immunoglobulin (Ig) after spontaneous miscarriage in a Rh-negative woman, with no anti-D antibodies.
  
  
  METHODS
  We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (31 December 2012).
  
  
  METHODS
  Randomised controlled trials (RCT) in Rh-negative women without antibodies who were given anti-D Ig following spontaneous miscarriage compared with no treatment or placebo treatment following spontaneous miscarriage as control.
  
  
  METHODS
  Two review authors independently assessed trials for inclusion and trial quality. Two review authors extracted data and checked it for accuracy.
  
  
  RESULTS
  We included one RCT, involving 48 women who had a miscarriage between eight to 24 weeks of gestation. Of the 19 women in the treatment group, 14 had therapeutic dilatation & curettage (D&C) and five had spontaneous miscarriage; of the 29 women in the control group, 25 had therapeutic D&C and four had spontaneous miscarriage. The treatment group received 300 µg anti-D Ig intramuscular injection and were compared with a control group who received 1 cc homogenous gamma globulin placebo.This review's primary outcomes (development of a positive Kleihauer Betke test (a test that detects fetal cells in the maternal blood; and development of RhD alloimmunisation in a subsequent pregnancy) were not reported in the included study.Similarly, none of the review's secondary outcomes were reported in the included study: the need for increased surveillance for suspected fetal blood sampling and fetal transfusions in subsequent pregnancies, neonatal morbidity such as neonatal anaemia, jaundice, bilirubin encephalopathy, erythroblastosis, prematurity, hypoglycaemia (low blood sugar) in subsequent pregnancies, maternal adverse events of anti-D administration including anaphylactic reaction and blood-borne infections.The included study did report subsequent Rh-positive pregnancies in three women in the treatment group and six women in the control group. However, due to the small sample size, the study failed to show any difference in maternal sensitisation or development of Rh alloimmunisation in the subsequent pregnancies.
  
  
  CONCLUSIONS
  There are insufficient data available to evaluate the practice of anti-D administration in an unsensitised Rh-negative mother after spontaneous miscarriage. Thus, until high-quality evidence becomes available, the practice of anti-D Immunoglobulin prophylaxis after spontaneous miscarriage for preventing Rh alloimmunisation cannot be generalised and should be based on the standard practice guidelines of each country.
authors.affiliation: Department of Obstetrics and Gynecology, Melaka Manipal Medical College, Melaka, Malaysia. karanthkl@ymail.com.
authors.forename: Laxminarayan
authors.initials: L
authors.lastname: Karanth
authors.forename: Sharifah Halimah
authors.initials: SH
authors.lastname: Jaafar
authors.forename: Sachchithanantham
authors.initials: S
authors.lastname: Kanagasabai
authors.forename: N S
authors.initials: NS
authors.lastname: Nair
authors.forename: Ankur
authors.initials: A
authors.lastname: Barua
mesh_terms: D000022:Abortion, Spontaneous / Q000276:immunology*; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D011247:Pregnancy; D016032:Randomized Controlled Trials as Topic; D012203:Rh Isoimmunization / Q000517:prevention & control*; D018029:Rho(D) Immune Globulin / Q000008:administration & dosage*
chemical_list: D007155:Immunologic Factors; D018029:Rho(D) Immune Globulin
references.citation: Lancet. 1969 Apr 5;1(7597):694-5
references.pmid: 4182652
references.citation: BMJ. 1997 Sep 13;315(7109):629-34
references.pmid: 9310563
references.citation: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010 Mar;154(1):3-7
references.pmid: 20445704
references.citation: Am J Obstet Gynecol. 1972 May 15;113(2):158-65
references.pmid: 4623673
references.citation: JAMA. 1991 Jun 26;265(24):3270-4
references.pmid: 1904504
references.citation: Clin Perinatol. 1995 Sep;22(3):545-59
references.pmid: 8521681
references.citation: Semin Perinatol. 1997 Feb;21(1):39-44
references.pmid: 9190032
references.citation: Br J Obstet Gynaecol. 1998 Nov;105 Suppl 18:11-8
references.pmid: 9863973
references.citation: Natl Vital Stat Rep. 2003 Dec 17;52(10):1-113
references.pmid: 14717305
references.citation: Cochrane Database Syst Rev. 2000;(2):CD000021
references.pmid: 10796089
references.citation: Br J Obstet Gynaecol. 1994 Apr;101(4):297-300
references.pmid: 8199074
references.citation: Lancet. 1963 Sep 7;2(7306):489-93
references.pmid: 14065420
references.citation: Scott Med J. 1994 Oct;39(5):147-9
references.pmid: 8778974
references.citation: Am J Obstet Gynecol. 1985 Feb 1;151(3):289-94
references.pmid: 2982267
references.citation: Stat Med. 2006 Oct 30;25(20):3443-57
references.pmid: 16345038
references.citation: Br J Obstet Gynaecol. 1998 Nov;105 Suppl 18:7-10
references.pmid: 9863972
references.citation: Cochrane Database Syst Rev. 2013 Feb 28;(2):CD000020
references.pmid: 23450526
references.citation: Int J Gynaecol Obstet. 1977;15(3):235-7
references.pmid: 416975